Tricarboxylic acid cycle related-metabolites and risk of atrial fibrillation and heart failure.


Journal

Metabolism: clinical and experimental
ISSN: 1532-8600
Titre abrégé: Metabolism
Pays: United States
ID NLM: 0375267

Informations de publication

Date de publication:
12 2021
Historique:
received: 05 07 2021
revised: 28 09 2021
accepted: 14 10 2021
pubmed: 23 10 2021
medline: 30 12 2021
entrez: 22 10 2021
Statut: ppublish

Résumé

Tricarboxylic acid (TCA) cycle deregulation may predispose to cardiovascular diseases, but the role of TCA cycle-related metabolites in the development of atrial fibrillation (AF) and heart failure (HF) remains unexplored. This study sought to investigate the association of TCA cycle-related metabolites with risk of AF and HF. We used two nested case-control studies within the PREDIMED study. During a mean follow-up for about 10 years, 512 AF and 334 HF incident cases matched by age (±5 years), sex and recruitment center to 616 controls and 433 controls, respectively, were included in this study. Baseline plasma levels of citrate, aconitate, isocitrate, succinate, malate and d/l-2-hydroxyglutarate were measured with liquid chromatography-tandem mass spectrometry. Multivariable conditional logistic regression models were fitted to estimate odds ratios (OR) and 95% confidence intervals (95% CI) for metabolites and the risk of AF or HF. Potential confounders included smoking, family history of premature coronary heart disease, physical activity, alcohol intake, body mass index, intervention groups, dyslipidemia, hypertension, type 2 diabetes and medication use. Comparing extreme quartiles of metabolites, elevated levels of succinate, malate, citrate and d/l-2-hydroxyglutarate were associated with a higher risk of AF [OR These findings underscore the potential role of the TCA cycle in the pathogenesis of cardiac outcomes.

Sections du résumé

BACKGROUND
Tricarboxylic acid (TCA) cycle deregulation may predispose to cardiovascular diseases, but the role of TCA cycle-related metabolites in the development of atrial fibrillation (AF) and heart failure (HF) remains unexplored. This study sought to investigate the association of TCA cycle-related metabolites with risk of AF and HF.
METHODS
We used two nested case-control studies within the PREDIMED study. During a mean follow-up for about 10 years, 512 AF and 334 HF incident cases matched by age (±5 years), sex and recruitment center to 616 controls and 433 controls, respectively, were included in this study. Baseline plasma levels of citrate, aconitate, isocitrate, succinate, malate and d/l-2-hydroxyglutarate were measured with liquid chromatography-tandem mass spectrometry. Multivariable conditional logistic regression models were fitted to estimate odds ratios (OR) and 95% confidence intervals (95% CI) for metabolites and the risk of AF or HF. Potential confounders included smoking, family history of premature coronary heart disease, physical activity, alcohol intake, body mass index, intervention groups, dyslipidemia, hypertension, type 2 diabetes and medication use.
RESULTS
Comparing extreme quartiles of metabolites, elevated levels of succinate, malate, citrate and d/l-2-hydroxyglutarate were associated with a higher risk of AF [OR
CONCLUSION
These findings underscore the potential role of the TCA cycle in the pathogenesis of cardiac outcomes.

Identifiants

pubmed: 34678258
pii: S0026-0495(21)00215-8
doi: 10.1016/j.metabol.2021.154915
pmc: PMC9206868
mid: NIHMS1816022
pii:
doi:

Substances chimiques

Glutarates 0
Isocitrates 0
Malates 0
alpha-hydroxyglutarate 2889-31-8
Citric Acid 2968PHW8QP
malic acid 817L1N4CKP
Aconitic Acid 93371T1BXP
isocitric acid 9RW6G5D4MQ
Succinic Acid AB6MNQ6J6L

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

154915

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL118264
Pays : United States

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest ER has received grants for research through his institution from the California Walnut Commission (CWC), as well as fees for lectures and participation in the CWC's Health Research Advisory Group, and support for travel and accommodation. He is also a non-paid member of the Scientific Advisory Council of the CWC. He has also received honoraria for Advisory Board, lectures and support for travel and accommodation from Alexion; honoraria for lectures and support for travel and accommodation from Danone; and honoraria for lectures from Amarin. JS-S is a non-paid member of the Scientific Committee of the International Nut and Dried Fruit Foundation. He has received grants/research support from the American Pistachio Growers and International Nut and Dried Fruit Foundation through his Institution. He has received honoraria from Instituto Danone Spain and Eroski. He is a member of the executive committee of Instituto Danone Spain and non-paid member of International Danone Institute. None of the other co-authors has potential conflicts of interest to disclose relevant to the subject matter or materials included in this work.

Références

Prog Cardiovasc Dis. 2006 Jan-Feb;48(4):256-69
pubmed: 16517247
N Engl J Med. 2007 Mar 15;356(11):1140-51
pubmed: 17360992
Int J Epidemiol. 2012 Apr;41(2):377-85
pubmed: 21172932
Circ Res. 2002 Nov 29;91(11):988-98
pubmed: 12456484
N Engl J Med. 1997 Nov 6;337(19):1360-9
pubmed: 9358131
Behav Brain Res. 2001 Nov 1;125(1-2):279-84
pubmed: 11682119
Anal Bioanal Chem. 2009 Jul;394(6):1517-24
pubmed: 19172251
Med Hypotheses. 2001 Oct;57(4):429-31
pubmed: 11601863
Circulation. 2014 Jul 1;130(1):18-26
pubmed: 24787471
Cell Metab. 2015 Aug 4;22(2):291-303
pubmed: 26212716
Cardiovasc Diabetol. 2017 Sep 29;16(1):120
pubmed: 28962617
Cardiovasc Res. 2017 Mar 15;113(4):411-421
pubmed: 28395011
Circ Cardiovasc Genet. 2014 Oct;7(5):711-9
pubmed: 25518044
PLoS Med. 2014 Feb 25;11(2):e1001606
pubmed: 24586121
Nat Commun. 2020 Jan 3;11(1):102
pubmed: 31900386
Circ J. 2017 Nov 24;81(12):1749-1757
pubmed: 29070758
Circulation. 2005 Dec 20;112(25):3868-75
pubmed: 16344383
Acta Physiol Scand. 2000 Apr;168(4):657-65
pubmed: 10759602
Bioanalysis. 2020 Aug;12(16):1149-1159
pubmed: 32757862
Circulation. 2009 May 12;119(18):2516-25
pubmed: 19433768
J Pharm Biomed Anal. 2013 Feb 23;74:178-85
pubmed: 23245249
Mol Biosyst. 2010 Jun;6(6):1061-70
pubmed: 20485748
Eur Heart J. 2005 Jun;26(11):1115-40
pubmed: 15901669
Oncologist. 2015 May;20(5):562-7
pubmed: 25862748
Circ Res. 2013 Aug 30;113(6):709-24
pubmed: 23989714
Am J Epidemiol. 1994 Jun 15;139(12):1197-209
pubmed: 8209878
J Proteome Res. 2011 Nov 4;10(11):4983-92
pubmed: 21902250
Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):706-11
pubmed: 19258478
Nat Med. 2011 Apr;17(4):448-53
pubmed: 21423183
J Clin Endocrinol Metab. 2004 Oct;89(10):4963-71
pubmed: 15472192
Eur J Heart Fail. 2017 Sep;19(9):1179-1185
pubmed: 28133855
ESC Heart Fail. 2017 May;4(2):178-189
pubmed: 28451455
Neurology. 2019 Feb 19;92(8):e802-e810
pubmed: 30674589
Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19611-6
pubmed: 22106302
Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10436-41
pubmed: 27582470

Auteurs

Mònica Bulló (M)

Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició Humana, Reus, Spain; Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; University Hospital of Sant Joan de Reus, Nutrition Unit, Reus, Spain.

Christopher Papandreou (C)

Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició Humana, Reus, Spain; Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; University Hospital of Sant Joan de Reus, Nutrition Unit, Reus, Spain.

Jesus García-Gavilán (J)

Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició Humana, Reus, Spain; Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; University Hospital of Sant Joan de Reus, Nutrition Unit, Reus, Spain.

Miguel Ruiz-Canela (M)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Navarra, Spain.

Jun Li (J)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Marta Guasch-Ferré (M)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division for Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, MA, USA.

Estefanía Toledo (E)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Navarra, Spain.

Clary Clish (C)

Broad Institute of MIT and Harvard University, Cambridge, MA, USA.

Dolores Corella (D)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Department of Preventive Medicine, University of Valencia, Valencia, Spain.

Ramon Estruch (R)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Department of Internal Medicine, Department of Endocrinology and Nutrition Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain.

Emilio Ros (E)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Lipid Clinic, Department of Endocrinology and Nutrition Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain.

Montserrat Fitó (M)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, Barcelona, Spain.

Chih-Hao Lee (CH)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Molecular Metabolism (C.-H.L.), Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Kerry Pierce (K)

Broad Institute of MIT and Harvard University, Cambridge, MA, USA.

Cristina Razquin (C)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Navarra, Spain.

Fernando Arós (F)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Department of Cardiology, University Hospital of Alava, Vitoria, Spain.

Lluís Serra-Majem (L)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Institute of Health Sciences IUNICS, University of Balearic Islands and Hospital Son Espases, Palma de Mallorca, Spain.

Liming Liang (L)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Statistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Miguel A Martínez-González (MA)

Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Navarra, Spain; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Frank B Hu (FB)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division for Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Statistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Jordi Salas-Salvadó (J)

Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició Humana, Reus, Spain; Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; University Hospital of Sant Joan de Reus, Nutrition Unit, Reus, Spain. Electronic address: jordi.salas@urv.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH